Últimas noticias sobre American Well (NYSE:AMWL) Bolsa

AMERICAN WELL CORP-CLASS A

American Well

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

American Well Corporation Class A Common Stock

American Well Corp

WIIM

Analog Devices shares are trading lower after Benchmark cut its price target on the stock from $275 to $260. Also, Needham reiterated a Hold rating.

Jim Lebenthal of Cerity Partners named Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) as his final trade on CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/22/final-trades-delta-air-lines-mercadolibre-toast-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; adding that people are flying and growth estimates <a href="https://www.benzinga.com/quote/DAL/analyst-ratings" target="_blank" rel="noopener">will</a><a href="https://www.benzinga.com/quote/DAL/analyst-ratings"> start going back higher</a>.
UBS analyst Thomas Wadewitz supported his view on Monday by upgrading Delta Air Lines from Neutral to Buy and raising the price target from $46 to $66.
Shannon Saccocia, chief investment officer of NB Private Wealth, said the iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) is undervalued because it is priced in with a lot of negative news.
Supporting her view, Paycom Software, on May 7, reported better-than-expected first-quarter earnings and sales.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova, senior managing director for Virtus Investment Partners, said MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) is the best consumer discretionary stock.
Adding support to his choice, MercadoLibre, on May 7, reported quarterly earnings of $9.74 per share which beat the analyst consensus estimate of $8.03 per share. The company reported quarterly sales of $5.93 billion which beat the analyst consensus estimate of $5.51 billion.
Joshua Brown, CEO of Ritholtz Wealth Management, named Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) his final trade.
Supporting his view, BMO Capital analyst Rufus Hone maintained Toast with an Outperform rating on May 12 and raised the price target from $44 to $45.
Price Action:
<ul class="wp-block-list">
<li>Delta Air Lines shares gained 0.5% to close at $48.50 on Thursday.</li>
<li>Toast shares fell 0.4% to close at $42.68 on Thursday.</li>
<li>MercadoLibre gained 0.2% to settle at $2,606.01 during Thursday's session.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45562909/top-2-financial-stocks-that-may-keep-you-up-at-night-in-may"> Top 2 Financial Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

iShares Dow Jones US Energy Sector Index Fund

MELI

TOST

Toast, Delta Air Lines, MercadoLibre And More On CNBC's 'Final Trades'

Maxim Group analyst Jason McCarthy downgrades Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) from Buy to Hold.

Downgrades

Analyst Ratings

CTXR

Maxim Group Downgrades Citius Pharmaceuticals to Hold

IMNN

IMUNON shares are trading higher after the company announced new data from its Phase 2 OVATION 2 Study of IMNN-001.

Macro Economic Events

Econ #s

Economics

USA Building Permits For April 1.422M Vs 1.412M Est.; 1.467M Prior

USA Building Permits (MoM) For April -4.0% Vs -4.7% Est.; 0.5% Prior

Leerink Partners analyst Joseph Schwartz upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Market Perform to Outperform and raises the price target from $4 to $12.

Upgrades

Price Target

FULC

Leerink Partners Upgrades Fulcrum Therapeutics to Outperform, Raises Price Target to $12

BKNG moves up 1.1% on a day the broad market was flat
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/22205109/Screenshot-2025-05-22-at-4.47.39%E2%80%AFPM-974x1024.png" alt="" class="wp-image-13313" /></figure>
Today, Booking Holdings Inc.(BKNG)&nbsp;experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 09:50AM on May 22nd, a significant trading signal occurred for Booking Holdings Inc., (BKNG) as it demonstrated a Power Inflow at a price of $5296.03. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $5296.03. The returns on the High price ($5351.80) and Close price ($5341.91) after the Power Inflow are 1.1% and 0.87%, respectively. This result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

Technicals

Opinion

Signals

BKNG

Booking Shares Climb 1.1% After Key Signal

ROST

Ross Stores shares are trading lower after the company issued Q2 EPS guidance below estimates.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54259095&amp;newsitemid=20250523411051&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b6399fb1ae2bead8534501a0ab8c6dfe">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025.
Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in a presentation titled, "Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial." The presentation will take place at 2:45pm CET on Saturday, May 31 at the Ensana Thermal Hotel Margitsziget in Budapest.

ATXS

Astria Therapeutics To Present Safety And Efficacy Data From Phase 1a And Phase 1b/2 Trials Of Navenibart At C1 Inhibitor Deficiency And Angioedema Workshop

<a href="https://www.cda-amc.ca/trastuzumab-deruxtecan-2" title="https://www.cda-amc.ca/trastuzumab-deruxtecan-2">https://www.cda-amc.ca/trastuzumab-deruxtecan-2</a>

Biotech

General

Canada's Drug Agency Issues AstraZeneca's Enhertu Time-Limited Reimbursement Recommendation

Dan Morehead, founder and CEO of Pantera Capital on Friday said <a href="https://www.benzinga.com/25/05/45560419/trumps-crypto-czar-david-sacks-foresees-stablecoin-bill-generating-trillions-for-us-treasury-practically-overnigh">the crypto industry</a> is poised to see a surge of public offerings, with companies like Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and Figure among those preparing to go public in the coming months.
What Happened: His <a href="https://www.cnbc.com/video/2025/05/21/pantera-capital-ceo-expects-wave-of-crypto-companies-to-go-public-in-next-6-months.html">comments</a> come amid what he described as a "flipping" of the U.S. regulatory environment, from a hostile stance to one that is now either "positive or at least neutral."
Morehead attributed this shift to multiple policy developments, including the SEC's rollback of Staff Accounting Bulletin 121, and new OCC guidance enabling banks to interact more directly with blockchain infrastructure. 
Combined, he said, these actions are unlocking long-constrained potential. 
"There are a lot of great companies that maybe should have gone public a few years ago," Morehead said. "In the next six months you're going to see a wave of great companies like Circle and Figure go public."
The renewed interest in U.S. capital markets for crypto is further underscored by strong demand from public investors. 
"MicroStrategy and other coin-based stocks prove people really want to invest in blockchain companies," he added.
Morehead emphasized this is not a short-term spike, but rather the beginning of a broader trend. 
"All of these companies have been kind of stuck in the pipe for the last two or three years," he said. "Now that they&#8217;re going public and each are going public today, it's trading up 35%, encourages other companies to go public. So I think it&#8217;s a big new trend."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45572374/xrp-dogecoin-shiba-inu-waiting-to-pump-they-dominate-mindshare-they-can-lead-in-culture-expert-says">XRP, Dogecoin, Shiba Inu Waiting To Pump: &#8216;They Dominate Mindshare, They Can Lead In Culture,&#8217; Expert Says</a>
Why It Matters: Pantera's optimism also stems from the rise of real-world assets on the blockchain, particularly in areas like stablecoins, tokenized treasuries, and on-chain mortgages.
He pointed to Pantera-backed projects such as Ondo Finance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>) and Figure, noting that Figure has already issued $40 billion worth of mortgages on blockchain rails, shaving off "over 100 basis points of friction."
When asked what further developments are needed to accelerate industry growth, Morehead highlighted regulatory clarity. 
"Uncertainty in the U.S. has driven innovation offshore," he said, noting that many companies previously relocated to jurisdictions like Singapore and the UAE due to hostility at home.
With the U.S. now appearing more open to blockchain innovation, he expects talent and capital to flow back.
Pantera is also actively participating in policy conversations in Washington, according to Morehead. "We're involved in a couple industry think tanks that advise the government. It's very important that blockchain happens in the U.S. rather than offshore."
As more companies up-list from international exchanges such as the TSX to U.S. markets, Morehead views this as a reversal of previous trends. "The U.S. has really been unique. Most countries have been neutral. Now the U.S. is going from being antagonistic to positive, and that helps people want a base in the U.S."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45571765/kraken-to-launch-247-tokenized-stock-trading-for-global-users-via-solana">Kraken To Launch 24/7 Tokenized Stock Trading For Global Users Via Solana</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ONDO

$USDC

Pantera CEO Predicts Surge In Crypto IPOs As US Regulatory Tone Turns Favorable

PicoCELA Inc. ("PicoCELA" or the "Company"), a Tokyo-based provider of enterprise wireless mesh solutions, today announced the pricing of a best-efforts public offering (the "Offering") of 6,100,000 American Depositary Shares ("ADSs") at a public offering price of $0.30 per ADS. The Company expects to receive aggregate gross proceeds of $1,830,000, before deducting placement agent commissions and other offering expenses. Each ADS represents one common share of the Company.
The Offering is expected to close on or about May 27, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use approximately 70% of the net proceeds from the Offering for working capital and general corporate purposes and approximately 30% for product development and research.

PCLA

PicoCELA Prices Best-Efforts Public Offering Of 6.1M ADSs At $0.30 Each, Targeting $1.83M In Gross Proceeds

JP Morgan analyst Tami Zakaria upgrades Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) from Neutral to Overweight and raises the price target from $225 to $277.

JP Morgan Upgrades Waste Management to Overweight, Raises Price Target to $277

Data show continuous&nbsp;clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group
Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years
Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology
LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gjJV-8pq5g3oh1gh2jUxuoxJ0F5LPAG3SU7issIrNRZCETVe_q2IlrAJcaJ5wQ5-9ZsXI4EUNHnps6gnEtaM-VqHf2_SdhwGIezCyprWiKe7JdIggh4sV23Y5iUqugYpLSEcgUXXzzFMYh2cT48PtMnU7hmhss-w0LiVOW6CIhcMXGfJlLqq14KIi5URF4Vmpp321Ua074W-y5CIsq-DCtYrRt1pPPODxGRibgtPD9pWkSMHsOUVo9W9Oq6QMejCDS-SOkTmorkYHd6Qvvcawbs5RAdw2yLVRM83xqb3XSegDpZHVnnhEloZA9JHP9oZnWOZ24q5NuOhA6e4XpE587QHr6nO3mo04hqJGhreX00=">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced new positive data from the Company's Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer. Results are being highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 - June 3, 2025, in Chicago, Illinois and virtually, and are also being published simultaneously in the peer-reviewed journal Gynecologic Oncology.
Based on the highly encouraging Phase 2 OVATION 2 Study results and following alignment with the U.S. Food and Drug Administration (FDA), IMUNON recently initiated the first two sites for its pivotal Phase 3 OVATION 3 Study of IMNN-001 in newly diagnosed advanced ovarian cancer.

IMUNON To Present New Data From Phase 2 OVATION 2 Study Of IMNN-001, Investigational Therapy For Treatment Of Advanced Ovarian Cancer At 2025 ASCO Annual Meeting

Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024
SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("SHOT", "Safety Shot", or the "Company"), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. ("Yerbae") after its recently announced acquisition of the company. With Yerbae's momentum into 2025, Safety Shot expects to leverage the brand's expanding retail presence, strong distributor network, and innovative product portfolio to accelerate growth and strengthen its market position. In addition, the Company anticipates a 1000% increase in 2025 annual revenue over 2024 following the acquisition, bringing significant additional shareholder value.

SHOT

Safety Shot Announces Strategic Plans To Capitalize On Growth Of Yerbae Brands; Acquisition Expected To Increase Safety Shot Annual Revenue By 1000 Percent Over 2024

<h3>Gainers</h3>
<ul>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares rose 43.0% to $1.28 during Friday's pre-market session. The market value of their outstanding shares is at $12.6 million. The company's, FY earnings came out 4 days ago. </li>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) shares rose 26.24% to $2.02. The company's market cap stands at $25.8 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares moved upwards by 11.7% to $4.2. The market value of their outstanding shares is at $2.4 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) stock moved upwards by 9.37% to $3.5. The market value of their outstanding shares is at $239.2 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares moved upwards by 8.19% to $0.85. The market value of their outstanding shares is at $8.9 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares increased by 6.97% to $0.27. The market value of their outstanding shares is at $9.5 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares fell 19.0% to $102.15 during Friday's pre-market session. The market value of their outstanding shares is at $15.5 billion. The company's, Q4 earnings came out yesterday. </li>
<li>MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) stock fell 15.28% to $18.8. The company's market cap stands at $5.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) shares fell 12.41% to $133.37. The market value of their outstanding shares is at $43.8 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) stock declined by 8.47% to $0.56. The market value of their outstanding shares is at $2.4 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares declined by 6.18% to $0.76. The market value of their outstanding shares is at $11.0 million. </li>
<li>Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) stock fell 6.11% to $6.77. The market value of their outstanding shares is at $2.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DECK

ECDA

INEO

LTRY

MNSO

NAMI

PTON

SBET

VLCN

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares rose 17.3% to $0.95 during Friday's pre-market session. The market value of their outstanding shares is at $38.3 million. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock moved upwards by 11.21% to $11.6. The market value of their outstanding shares is at $219.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares increased by 10.18% to $1.73. The market value of their outstanding shares is at $79.0 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock moved upwards by 10.0% to $1.32. The company's market cap stands at $86.9 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares moved upwards by 9.47% to $6.7. The market value of their outstanding shares is at $361.6 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock rose 9.42% to $4.41. The market value of their outstanding shares is at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares declined by 20.7% to $12.42 during Friday's pre-market session. The market value of their outstanding shares is at $677.3 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares fell 16.5% to $2.01. The market value of their outstanding shares is at $56.1 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares fell 14.64% to $1.4. The market value of their outstanding shares is at $46.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 13.67% to $1.2. The company's market cap stands at $3.0 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares decreased by 8.31% to $0.31. The company's market cap stands at $7.1 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 7.84% to $0.51. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BCAX

BDRX

BRNS

BWAY

IMMX

IOBT

OTLK

PDSB

TSBX

12 Health Care Stocks Moving In Friday's Pre-Market Session

JP Morgan analyst Tami Zakaria downgrades GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) from Overweight to Neutral and raises the price target from $51 to $54.

JP Morgan Downgrades GFL Environmental to Neutral, Raises Price Target to $54

<h3>Gainers</h3>
<ul>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares rose 26.8% to $5.35 during Friday's pre-market session. The company's market cap stands at $40.5 million. </li>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares increased by 14.5% to $25.0. The company's market cap stands at $48.8 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares moved upwards by 14.04% to $3.41. The company's market cap stands at $12.1 million. </li>
<li>FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) stock increased by 14.0% to $5.7. The market value of their outstanding shares is at $654.1 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares increased by 7.92% to $0.94. The market value of their outstanding shares is at $16.2 million. </li>
<li>NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) stock increased by 7.46% to $27.21. The market value of their outstanding shares is at $3.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) shares declined by 23.2% to $2.55 during Friday's pre-market session. The company's market cap stands at $21.1 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares decreased by 14.92% to $7.7. The market value of their outstanding shares is at $131.3 million. </li>
<li>Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares decreased by 11.51% to $114.28. The market value of their outstanding shares is at $14.1 billion. The company's, Q4 earnings came out today. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 10.66% to $0.89. The market value of their outstanding shares is at $12.7 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock fell 8.86% to $0.51. The market value of their outstanding shares is at $3.6 million. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares decreased by 7.02% to $0.73. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

American Well

Noticias

Últimas noticias sobre American Well (NYSE:AMWL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL